

1 **Effect of *Bacillus coagulans* Unique IS-2 in Inflammatory Bowel Disease (IBD): A**
2 **Randomized Controlled Trial**

3
4 V Deepak Bamola¹, Divya Dubey¹, Projoyita Samanta¹, Saurabh Kedia², Ratna Sudha
5 Madempudi³, Jayanthi Neelamraju³, Vineet Ahuja², Rama Chaudhry^{1*}

6
7 ¹ Department of Microbiology, ² Department of Gastroenterology,
8 All India Institute of Medical Sciences, New Delhi, India

9 ³ Centre for Research & Development, Unique Biotech Ltd., Plot No. 2, Phase-II,
10 Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India

11 *Corresponding author

12
13 **Abstract**

14
15 Probiotic intervention is an important approach for the treatment and health
16 restoration in inflammatory bowel disease (IBD). A study was conducted to assess the effect
17 of *Bacillus coagulans* Unique IS-2 in IBD patients. Recruited subjects were given either
18 probiotic *B. coagulans* Unique IS-2 or placebo for 4 weeks as per randomization. Survival of
19 the given probiotic strain in GI, presence of beneficial gut bacteria, serum cytokines, serum
20 serotonin and serum dopamine, symptoms of disease, physical, behavioral and psychological
21 parameters of the subjects were evaluated before and after intervention. In this study *B.*
22 *coagulans* Unique IS-2 was well tolerated with no severe adverse events in IBD patients and
23 demonstrated good survival in GI tract by significantly high detection in probiotic treated
24 group (p <0.001). Significant enhancement in beneficial *Lactobacilli* was observed in
25 probiotic treated group (p <0.01). Metagenomic analysis also showed an increase in the
26 abundance of bacterial genera *Bacillus*, *Lactobacillus*, *Bifidobacterium*, *Faecalibacterium*,
27 *Bacteroides*, *Megamonas*, *Lachnospira*, *Blautia*, *Alistipes* and decrease in *Sutterella*,
28 *Dialister*, *Roseburia* and *Megasphaera* was observed in the post intervention samples in the
29 treatment group. Increased secretion of cytokine IL-10 and variable decrease in the secretion
30 of IL-6, IL-1 β , TNF- α , IL -17 and IL -23 was observed in in the probiotic treated group.
31 Post intervention change in serum serotonin and serum dopamine was not significant in both
32 the groups. A reduction in the severity of disease symptoms and improvement in the
33 physical, behavioral and psychological parameter was observed in the probiotic treated
34 group. The observed results demonstrated that *B. coagulans* Unique IS-2 with SMT was
35 effective in adult IBD patients. Study was registered with Clinical Trials Registry India
36 (CTRI) - (registration no.- CTRI/2019/11/022087).

37
38 **Keywords:** Inflammatory bowel disease (IBD), Gut Microbiota, Probiotic, *Bacillus*
39 *coagulans*, Cytokines, Randomized Controlled Trial (RCT)

40

Introduction

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Inflammatory bowel disease (IBD) is a gastrointestinal (GI) disease characterized by chronic inflammation. The incidence of IBD is rising all over the world¹ including Asia². Across the globe India is projected to have one of the highest IBD burden in spite of having lower prevalence as compared to the West^{3,4}. IBD significantly diminishes the quality of life of the affected individuals by disturbing health, daily work, education, and social relationships which cause a considerable impact on health and economy⁵. Etiology and pathogenesis of IBD is multi-factorial and involves genetics, ethnicity, diet, lifestyle, environmental factors, immunity and gut microbiota of the individual^{6,7}. Higher stress level and disturbance in psychology in IBD patients may trigger the inflammation and increases the severity of disease⁸.

The human gut microbiota has demonstrated physiological functions associated with homeostasis, nutrition, immunity and defense of the host. Normally the gut maintains a homeostatic condition but in IBD this homeostasis gets disturbed and leads to intestinal inflammation⁹. Down-regulation of the immune responses may allow the damaged site to heal and reset the normal physiological functions⁷. Alteration in the gut microbiota, referred to as dysbiosis, plays a key role in the pathogenesis of IBD^{10,11}. Dysbiosis may occur in both inflamed and non-inflamed areas in patients¹² and is well recognized sign of IBD¹³. Modification of gut microbiota with probiotic intervention to attenuate inflammatory activity and prevent relapses in IBD are considered as an important approach for treatment and health restoration in IBD^{11,14} by relieving intestinal dysbiosis and GI inflammation¹⁰.

GI disorders modulate the gut function and influence the emotional and cognitive factors including mood, anxiety, pain and negative effects, decision making, restlessness. This change in emotional and cognitive factors may be associated with serum serotonin and dopamine in IBD patients¹⁵. The lowering of serotonin levels can result in mood disorders, such as anxiety or depression and hence consider playing an important role in regulating physical and psychological symptoms¹⁶ and activation of immune response and gut inflammation¹⁵. Dopamine is an important neurotransmitter which affects behavior, psychology, immune functions and GI functions and its unregulated production in IBD is already reported¹⁷. Evaluation of these factors has turn out to be an important factor to monitor the severity of the disease. Gut microbiota and probiotics have demonstrated the effect on behavior, psychology, mood, and cognition^{18,19}.

74 *Bacillus* strains are stable at room temperature and hence gaining a lot of attention. *B.*
75 *coagulans* is a spore-forming, gram-positive, non-pathogenic, facultative anaerobic, lactic
76 acid-producing bacteria and resistant to high temperatures²⁰. *B. coagulans* Qualified
77 Presumption of Safety (QPS) list²¹ and has been reported Generally Recognized as Safe
78 (GRAS) and considered safe by European Union Food Safety Authority (EFSA) and US
79 Food and Drug Administration (FDA). *B coagulans* Unique IS-2 (ATCC PTA-11748,
80 MTCC 5260) is a shelf-stable, resistant to bile acids and acidic conditions of the stomach,
81 clinically established probiotic strain and with proven safety and efficacy in the treatment of
82 constipation, diarrhea²²⁻²⁵ bacterial vaginosis²⁶ and irritable bowel syndrome (IBS)²⁷. In this
83 study we assessed the effect of *B coagulans* Unique IS-2 on adults with inflammatory bowel
84 disease (IBD) receiving standard medical treatment (SMT). Survival of the given probiotic *B*
85 *coagulans* Unique IS2 in the gut, presence of beneficial gut bacteria, serum cytokines,
86 serotonin and dopamine, IBD symptoms, physical and psychological parameters were
87 evaluated before and after intervention.

88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121

Methodology

- **Study design:** Randomized, double blind, placebo controlled trial. Study was registered with Clinical Trials Registry (CTRI) India (CTRI/2019/11/022087).
- **Site:** Outpatients from a tertiary care hospital.
- **Ethical approval and written informed consent:** Ethical approval for the study was obtained from Institute Ethics Committee of AIIMS, New Delhi, India (Ref – IEC.478/07.10.2016.OP-7). Expected duration of participation, expected benefits, associated risks, and maintenance of confidentiality of records were explained to each participant and a written informed consent was obtained before enrollment in the study.
- **Subject / Selection of patients:** Clinically diagnosed adult patients of ulcerative colitis (UC) with mild to moderate severity between age group (18–60 years) under standard Medical treatment (SMT) patients were included. Simple Clinical Colitis Activity Index (SCCAI) score²⁸ was used to quantify UC disease activity. SCCAI score was calculated by evaluating different disease symptoms including bowel frequency, urgency of defecation, blood in stool, abdominal cramps and general wellbeing of the patients. SMT for the enrolled patient in this study was 5-aminosalicylic acid (5-ASA) - Sulfasalazine (3 grams/ day) or Mesalamine 800 mg orally 3 times a day.
- **Inclusion criteria:** (a) Adult patient clinically diagnosed with Ulcerative Colitis (UC), (b) patients of either sex of the age range from 18-60 year, (d) patient ready to participate in the study and giving written consent, (e) patient visiting to Out Patient Department (OPD) of AIIMS for treatment.
- **Exclusion criteria:** (a) Patient diagnosed with any kind of carcinoma, (b) Patient diagnosed with any other gastrointestinal disease, (c) Patient suffering from Immunodeficiency disorder, (d) Patient is taking any probiotic drug/ or having consumed probiotic in the last one month, (e) patient not taking food through oral route, (f) Patient having undergone any kind of gastrointestinal surgery in the last three month.
- **Enrolment of patients:** After establishing the eligibility on screening, a total of 100 patients were recruited and randomized. Patients were called for baseline visit (day 0). Medical history, medications, physical examination and vital signs were assessed during hospital visit. *B. coagulans* Unique IS-2 (2billion-CFU/capsule) twice in day (total 4 billion CFU / per day) or placebo (matching in size and appearance, contained only excipient, maltodextrin) twice in a day was given to qualified patients for 4 weeks followed by observation and telephonic follow-up of dose compliance.

- 122 ▪ **Sample size determination:** Statistical software STATA (Version 14, USA) was used for
123 sample calculation. To identify presence of proportion difference the assumption was
124 made that minimum of 118 subjects required to be screened and 94 patients required
125 assessing the endpoint in the study which will reject the null hypothesis.
- 126 ▪ **Intervention:** Fully characterized FDA / DCGI/ FSSAI approved probiotic strain *Bacillus*
127 *coagulans* Unique IS-2 (ATCC PTA-11748, MTCC 5260) was used as an intervention
128 agent in this study for 4 weeks along with placebo as per randomization. The patients
129 were explained to consume one capsule post meal twice a day for 4 weeks along with the
130 SMT. The compliance was ensured by telephonic follow-up and scheduled hospital visits.
- 131 ▪ **Randomization:** Computerized permuted blocks randomization was done in 1:1 ratio and
132 generated by nQuery clinical trial design platform / Sample Size Software. It consisted of
133 two phases: screening, baseline visit 1 (week 0 / day 0), visit 2 (1 week after completing
134 intervention / week 5). The randomization codes were kept blinded.
- 135 ▪ **Outcome measures:** The efficacy outcomes were measured after administration by (i)
136 detection of *Bacillus coagulans* Unique IS-2, (ii) Change in beneficial Lactobacillus and
137 other gut microbiota, (iii) Change in pro and anti-inflammatory cytokines, (iv) Change in
138 symptoms of the disease, (v) Change in serum concentration of serotonin and dopamine,
139 (vi) Changes in physical and psychological parameters. Each participant was requested to
140 answer the designed questionnaire for the assessment of physical, behavioral and
141 psychological parameters as per the Hopkins Symptom Checklist (HSCL): A self-report
142 symptom inventory^{29,30}. Physical parameters including muscle stiffness, heartburn,
143 headache, shakiness, sleep problem, difficulty in completing work, procrastination,
144 overwhelming, feeling of depression, trouble relaxing, nervousness, poor concentration,
145 restlessness and quick temper were evaluated. Parameters were evaluated based on scores,
146 the decrease in the score indicating the reduction in the severity of symptoms and increase
147 in the score indicating an augmentation in the severity of the symptom.
- 148 ▪ **Safety evaluation:** Safety of investigational product was assessed by adverse event
149 reporting. During hospital visit of the patient physical examination, monitoring of vital
150 signs and routine laboratory investigations.
- 151 ▪ **Sample collection and processing:** A stool sample in a sterile container and a blood
152 sample in a plain vial were collected from each enrolled subject before and after
153 intervention. Stool samples were aliquoted and processed for microbial identification and
154 bacterial DNA isolation. Blood samples were processed for serum separation for cytokine
155 assays, serotonin and dopamine concentration.

156 ▪ **Microbial culture and identification:** *B. coagulans* Unique IS-2 and *Lactobacillus spp.*
157 were checked in each patient before and after intervention using different bacterial media.
158 Mueller Hinton (MH) broth and agar (Difco Laboratory, Detroit, MI) was used for the
159 cultivation of *Bacillus* strains. Sample were incubated for 24 hours at 37°C in MH broth
160 and then plated on MH agar plate. de Man, Rogosa and Sharpe (MRS) broth and agar
161 (Difco Laboratory, Detroit, MI) was used to grow *Lactobacillus*. The stool sample were
162 incubated for 48 hours at 37°C in MRS broth in Anaerobic Glove Box (Anaerobic
163 Workstation-Whitley DG250-DonWhitley Scientific, United Kingdom) in anaerobic
164 condition and then plated on MRS agar plate. The isolated colonies were identified by
165 standard culture and biochemical method, matrix-assisted laser desorption / ionization-
166 (MALDI-and the mass analyzer is time-of-flight (TOF) analyzer (bioMérieuxInc, USA)
167 and molecular method.

168 ▪ **Molecular identification of Bacteria:** *B. coagulans* was identified via 16S rRNA
169 sequencing using published primers: forward 5'-ACAGGGCTTTCAGATACCCG-3' and
170 reverse 5'-CGGGGATCCGTCCATCAAAA-3'. Sequence similarity was checked using
171 BLAST, NCBI and it was 96% identical. A known strain of *B. coagulans* Unique IS-2
172 was used as a positive control. The reaction mixture consisted of 0.5µl of dNTP (10mM),
173 0.5ul of DNA template (177ng/µl), 2.5 µl of reaction buffer (10X) with MgCL2, 0.5ul of
174 each of primers (pm/µl), 0.5µl of 5U/µlTaq DNA polymerase (Thermo Scientific, USA)
175 and 20 µl of nuclease free H₂O. Denaturation was done at 94°C for 5min, followed by 30
176 cycles consisting of, 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min which has been
177 ended by a final amplification step at 72°C for 8min, using the PCR machine (Applied
178 Biosystems, USA). PCR product was analyzed by the electrophoresis in 1% agarose gel
179 and gel bands were observed and recorded using via Gel Doc System (BioRad, USA).

180 **Next generation sequencing (NGS) of Gut microbiota-**

181 ▪ **Fecal samples collection and DNA isolation:** Fecal samples were collected in sterile
182 container and processed for DNA isolation. Total DNA was extracted by using QIAamp
183 DNA Stool Mini Kit (Qiagen) with some modification to increase DNA yield³¹. The
184 quality and quantity of DNA was checked by Nanodrop (TECAN Nano quant). 16S rRNA
185 amplicon sequencing was performed using Illumina MiSeq® sequencing system (Illumina,
186 San Diego, CA, USA).

187 ▪ **Sequencing Methodology:** Bacterial 16S rRNA hyper variable regions V3-V4 were
188 amplified using V3-V4F (CCTACGGGNGGCWGCAG) and V3-V4R
189 (GACTACHVGGGTATCTAATCC) primers. 25ng of DNA was used for PCR

190 amplification using KAPA HiFi HotStart Ready Mix. The PCR was performed with
191 standard protocol and the amplicons were purified using Ampure beads to remove unused
192 primers. The amplicon product was amplified with Illumina primers to generate
193 sequencing libraries. Qubit dsDNA assay kit was used for libraries preparation.
194 Sequencing was done using Illumina Miseq with 2x300PE sequencing kit. The sequence
195 data quality was checked using FastQC and MultiQC software.

196 ■ **Data Analysis:** The analysis was done as per standard methodology³². Only QC passed
197 reads were transferred into mothur and the pairs were aligned. The ambiguous contigs
198 were rejected and duplicates were merged. Chimeric sequences were identified by a
199 known reference and UCHIME algorithm was used. Using Silva v.132 database final
200 filtered contigs were classified into taxonomical outlines and clustered into Operational
201 Taxonomic Unit (OTUs) and abundance was calculated. Alpha diversity was assessed for
202 richness and relative abundance of bacteria. Chao1 and ACE indices were used for
203 richness and Shannon, Simpson, and Fisher were used for both richness and relative
204 abundance. Kruskal-Wallis rank sum test was carried out to identify statistically
205 significant difference among OTUs abundance between groups.


206 ■ **ELISA for Cytokines, serum serotonin and dopamine:**

207 Serum samples were tested and quantified for IL10, IL6, IL17, IL23, IL 1 β , TNF, serum
208 serotonin and dopamine as per standard protocol and manufacture's instruction (Fine Test,
209 Fine Biotech Co. Ltd). In brief, standards and test samples were added to 96 well plates
210 and incubated at 37⁰C for 90 min. After incubation, wells were washed with wash buffer
211 and secondary antibody were added and incubated at 37⁰C for 60 min. Further, wells were
212 washed and HRP-Streptavidin was added and incubated at 37⁰C for 30 min. Multiple
213 washing was done with the wash buffer to wash unbound conjugates. TMB substrates
214 were used to visualize HRP enzymatic reaction. Absorbance at 450 nm has been
215 measured using the microplate reader (Nanodrop, Nanoquant Infinite M 200 Pro (Texan,
216 Austria GmbH) and the concentration were calculated.

217 ■ **Data analysis:** Here we have reported the analysis of data of the patients of ulcerative
218 colitis (UC). Data from 48 subjects in treatment group and 49 subjects in placebo group
219 were analysed. Statistical analysis was done by STATA statistical software (Version 14,
220 USA). Statistical evaluation of parameters was assessed by Chi-square / two sample *t*-test
221 and *p* value < 0.05 was considered as statistically significant.

222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256

'CONSORT' Flow Chart



257

Results

258

259 **Survival of *Bacillus coagulans* Unique IS2 in the gut**

260 The samples of the enrolled subjects in the both treatment and placebo group were
261 assessed for the presence of *Bacillus coagulans* Unique IS-2 before and after treatment. No *B*
262 *coagulans* was detected in pre-treatment sample in both the groups. In the probiotic treated
263 group *B coagulans* was detected in 65.21 % subjects by microbial culture method and 76.08
264 % subjects by molecular method which was significant as compared to placebo ($p < 0.0001$).
265 The samples from the subjects of placebo group were also assessed for the presence of *B*
266 *coagulans* with no *B coagulans* being detected in placebo group by both microbial and
267 molecular methods. These results indicate that the probiotic strain *B coagulans* Unique IS-2
268 was able to survive in GI tract of recruited IBD patients.

269

270 **Detection of beneficial Lactobacilli by microbial culture method**

271 The samples of the enrolled IBD patients in both probiotic treated group and placebo
272 group were assessed for the presence of beneficial Lactobacilli, before and after intervention.
273 Results revealed that in the probiotic treated group, beneficial *Lactobacilli* were detected in
274 54.34 % and 78.26 % patients before and after intervention respectively. In the placebo
275 group beneficial *Lactobacilli* were detected in 52.08 % and 47.91 % of patients before and
276 after intervention respectively. The detection of beneficial *Lactobacilli* after intervention in
277 the probiotic treated group was significantly high ($p < 0.01$) which indicated that the probiotic
278 strain *Bacillus coagulans* Unique IS-2 was able to enhance the presence of beneficial
279 *Lactobacilli* in recruited IBD patients.


280

281 **Next generation Sequencing (NGS) and Metagenomic analysis of gut microbiota**

282 **Phyla:** Operational Taxonomic Unit (OTUs) were calculated for different bacterial taxon
283 including phyla, class, orders, families, genera and species before and after intervention in
284 both probiotic treated and placebo group. Analysis revealed phylum Firmicutes
285 Bacteroidetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were
286 abundant in both the groups. The average % OTUs of phylum *Firmicutes* were in 33.13%
287 and 36.23% in pre and post intervention sample respectively in treatment group and 37.90%
288 and 42.89% in placebo group. The average % OTUs of phylum *Bacteroidetes* were in
289 40.12% and 40.28% in pre and post intervention sample respectively in treatment group and
290 32.49% and 40.28% in pre and post intervention sample respectively in placebo group.
291 OTUs of phylum *Bacteroidetes* were significantly increased in post intervention sample in

292 placebo group. The average % OTUs of phylum *Proteobacteria* were in 12.90% and 7.50%
 293 in pre and post intervention sample respectively in treatment group and 16.75% and 6.21% in
 294 placebo group. The average % OTUs of phylum *Actinobacteria* were in 6.64% and 4.29% in
 295 pre and post intervention sample respectively in treatment group and 8.62% and 2.04% in
 296 placebo group. Decrease in OTUs of phylum *Proteobacteria* and phylum *Actinobacteria*
 297 was significant in the treatment group. The average % OTUs of phylum *Euryarchaeota* were
 298 in 1.02% and 2.36% in pre and post intervention sample respectively in treatment group and
 299 2.03% and 0.55% in placebo group. OTUs of phylum *Euryarchaeota* were increased in post
 300 intervention sample in treatment group and decreased in placebo group. The average %
 301 OTUs of phylum *Verrucomicrobia* were in 0.01% and 0.04% in pre and post intervention
 302 sample respectively in treatment group and 0.96% and 0.10% in placebo group. OTUs of
 303 phylum *Verrucomicrobia* were increased in post intervention sample in treatment group and
 304 decreased in placebo group.

305 **Figure 1: Abundance of major bacterial phyla**




306

307 **Class:** The average % OTUs of class *Bacteroidia* were 40.11% and 40.27% in pre and post
 308 intervention sample respectively in treatment group and 32.48% and 43.63% pre and post
 309 intervention sample respectively in placebo group. An increase in OTUs of class *Bacteroidia*

310 was significant in the placebo group. The average % OTUs of class Clostridia were 15.20%
 311 and 22.09% in pre and post intervention sample respectively in treatment group and 20.79%
 312 and 28.82% in pre and post intervention sample respectively in placebo group. The average
 313 % OTUs of class Gammaproteobacteria were 12.87 % and 7.41% in pre and post intervention
 314 sample respectively in treatment group and 16.72% and 6.16% respectively in placebo group.
 315 The average % OTUs of class Negativicutes were 7.96% and 6.35% in pre and post
 316 intervention sample respectively in treatment group and 3.49% and 7.22% respectively in
 317 placebo group. A decrease was observed in OTUs of class Negativicutes in post intervention
 318 samples of treatment group and an increase in post intervention samples in placebo group.
 319 The average % OTUs of class Methanobacteria were 1.02% and 2.36% in pre and post
 320 intervention sample respectively in treatment group and 2.03% and 0.55% in placebo group.
 321 An increase in OTUs of class Methanobacteria in post intervention samples was observed in
 322 treatment group and decrease in OTUs of class Methanobacteria in placebo group. The
 323 average % OTUs of class Actinobacteria were 3.49% and 1.81% in pre and post intervention
 324 sample respectively in treatment group and 7.76% and 1.64% pre and post intervention
 325 sample respectively in placebo group.


326 **Figure 2: Abundance of major bacterial classes**



327

328 **Order:** The average % OTUs of Bacteroidales were 39.94% and 40.03% in pre and post
329 intervention sample respectively in treatment group and 32.37% and 43.46% in placebo
330 group. A significant increase in OTUs of order Bacteroidales in post intervention samples
331 was observed in placebo group. The average % OTUs of order Clostridiales was 15.19%
332 and 22.08% in pre and post intervention sample respectively in treatment group and 20.79%
333 and 28.81% in placebo group. The average % OTUs of order Selenomonadales was 8.02%
334 and 6.30 % in pre and post intervention sample respectively in treatment group and 3.49%
335 and 7.22% in placebo group. A decrease in OTUs of order Selenomonadales in post
336 intervention samples in treatment group and increase in post intervention samples in placebo
337 group. The average % OTUs of order Lactobacillales was 1.67% and 2.49% in pre and post
338 intervention sample respectively in treatment group and 10.66% and 3.82% in placebo group.
339 An increase in OTUs of order Lactobacillales was observed in post intervention samples in
340 treatment group and decrease in post intervention samples in placebo group. The average %
341 OTUs of order Erysipelotrichales was 7.00% and 5.03% in pre and post intervention sample
342 respectively in treatment group and 2.48 % and 2.48% in placebo group. A decrease in
343 OTUs of order Erysipelotrichales in post intervention samples in treatment group and
344 increase in placebo group were observed. The average % OTUs of order Bifidobacteriales
345 were 1.74% and 3.55% in pre and post intervention sample respectively in treatment group
346 and 7.71% and 1.61% respectively in placebo group. An increase in OTUs of order
347 Bifidobacteriales in post intervention samples in treatment group and decrease in placebo
348 group were observed.

349 **Figure 3: Abundance of major bacterial orders**




350

351 **Family:** The average % OTUs of family Prevotellaceae was 32.66% and 33.20% in pre and
 352 post intervention sample respectively in treatment group and 8.62% and 31.96% in placebo
 353 group. Significant increase was observed in OTUs of family Prevotellaceae in post
 354 intervention samples in placebo group. The average % OTUs of family Ruminococcaceae
 355 was 8.22% and 11.99% in pre and post intervention sample respectively in treatment group
 356 and 12.34% and 12.23% in placebo group. Increase in OTUs of family Ruminococcaceae in
 357 post intervention samples in treatment group and decrease in placebo group. The average %
 358 OTUs of family Bacteroidaceae was 4.09% and 4.58 % in pre and post intervention sample
 359 respectively in treatment group 22.85% and 9.44% in placebo group. Increase in OTUs of
 360 family Bacteroidaceae in post intervention samples in treatment group and decrease in
 361 placebo group were observed. The average % OTUs of family Lachnospiraceae was 6.14 %
 362 and 8.40 % in pre and post intervention sample respectively in treatment group and 6.79 %
 363 and 13.48 % respectively in placebo group. The average % OTUs of family Veillonellaceae
 364 was 7.47% and 5.72 % in pre and post intervention sample respectively in treatment group
 365 and 3.49 % and 7.15% in placebo group. Decrease in OTUs of family Veillonellaceae in post
 366 intervention samples in treatment group and increase in placebo group were observed. The

367 average % OTUs of family Enterobacteriaceae was 4.69 % and 3.14 % in pre and post
 368 intervention sample respectively in treatment group and 9.79% and 2.41 % respectively in
 369 placebo group. A significant decrease was observed in OTUs of family Enterobacteriaceae in
 370 post intervention samples in placebo group. The average % OTUs of family Lactobacillaceae
 371 was 1.12% and 2.03% in pre and post intervention sample respectively in treatment group
 372 and 6.36 % and 3.22 % respectively in placebo group. Increase in OTUs of family
 373 Lactobacillaceae in post intervention samples in treatment group and decrease in placebo
 374 group were observed. The average % OTUs of family Bifidobacteriaceae was 1.74% and
 375 3.55% in pre and post intervention sample respectively in treatment group and 7.71% and
 376 1.61% respectively in placebo group. Increase in OTUs of family Bifidobacteriaceae in post
 377 intervention samples in treatment group and decrease in placebo group were observed.

378 **Figure 4: Abundance of major bacterial families**



379

380


381 **Genera:** The average % OTUs of genus *Prevotella* were 26.37% and 22.10% in pre and post
 382 intervention sample respectively in treatment group and 10.28% and 25.57% respectively in
 383 placebo group. Decrease in OTUs of genus *Prevotella* in post intervention samples in
 384 treatment group and an increase in placebo group was observed. The average % OTUs of

385 genus *Bacteroides* were 4.88% and 6.13% in pre and post intervention sample respectively in
386 treatment group and 19.96% and 7.89% respectively in placebo group. An increase in OTUs
387 of genus *Bacteroides* in post intervention samples in treatment group and decrease in placebo
388 group were observed. Average % OTUs of genus *Faecalibacterium* were 6.56% and 6.87%
389 in pre and post intervention sample respectively in treatment group and 9.23% and 8.01%
390 respectively in placebo group. An increase in OTUs of genus *Faecalibacterium* in post
391 intervention samples in treatment group and decrease in placebo group were observed. The
392 average % OTUs of genus *Lactobacillus* were 1.21% and 2.59% in pre and post intervention
393 sample respectively in treatment group and 7.33% and 3.49% respectively in placebo group.
394 An increase in OTUs of genus *Lactobacillus* in post intervention samples in treatment group
395 and decrease in placebo group were observed. The average % OTUs of genus
396 *Bifidobacterium* were 1.67% and 4.44% in pre and post intervention sample respectively in
397 treatment group and 6.03% and 1.42% respectively in placebo group. An increase in OTUs
398 of genus *Bifidobacterium* in post intervention samples in treatment group and decrease in
399 placebo group were observed. The average % OTUs of genus *Bacillus* were 0.01% and
400 0.04% in pre and post intervention sample respectively in treatment group and 0.001% and
401 0.001% respectively in placebo group. OTUs of Genus *Bacillus* in post intervention samples
402 in treatment group were high while OTUs of genus *Bacillus* in placebo group were very low.
403 The average % OTUs of genus *Escherichia* were 3.61% and 1.24% in pre and post
404 intervention sample respectively in treatment group and 11.06% and 1.81% in placebo group.
405 The average % OTUs of genus *Sutterella* were 3.05% and 2.22% in pre and post intervention
406 sample respectively in treatment group and 3.60% and 1.68% in placebo group. The average
407 % OTUs of genus *Dialister* were 3.37% and 1.98% in pre and post intervention sample
408 respectively in treatment group and 0.09% and 3.66% respectively in placebo group. A
409 decrease in OTUs of genus *Dialister* was observed in post intervention samples in treatment
410 group and increase in placebo group. The average % OTUs of genus *Megamonas* were
411 1.39% and 2.17% in pre and post intervention sample respectively in treatment group and
412 0.73% and 0.001% respectively in placebo group. An increase in OTUs of genus
413 *Megamonas* was observed in post intervention samples in treatment group and decrease in
414 placebo group. The average % OTUs of genus *Roseburia* were 0.82% and 0.45% in pre and
415 post intervention sample respectively in treatment group and 1.18% and 2.46% in placebo
416 group. A decrease in OTUs of genus *Roseburia* was observed in post intervention samples in
417 treatment group and increase in placebo group. The average % OTUs of genus *Megasphaera*
418 were 2.37% and 0.36% in pre and post intervention sample respectively in treatment group

419 and 2.02% and 1.97% in placebo group. A decrease in OTUs of genus *Megasphaera* was
 420 observed in post intervention samples in both treatment and placebo group. The average %
 421 OTUs of genus *Lachnospira* were 0.42% and 0.34% in pre and post intervention sample
 422 respectively in treatment group and 1.49% and 2.83% in placebo group. An increase in
 423 OTUs of genus *Lachnospira* was observed in post intervention samples in treatment group
 424 and decrease in placebo group. The average % OTUs of genus *Blautia* were 0.25% and
 425 0.40% in pre and post intervention sample respectively in treatment group and 0.12% and
 426 0.25% in placebo group. An increase in OTUs of genus *Blautia* was observed in post
 427 intervention samples in both treatment and placebo group. The average % OTUs of genus
 428 *Alistipes* were 0.08% and 0.37% in pre and post intervention sample respectively in treatment
 429 group and 0.12% and 0.04% in placebo group. An increase in OTUs of genus *Alistipes* in
 430 post intervention samples in treatment group and decrease in placebo group were observed.

431
 432

Figure 5: Abundance of major bacterial genera



433

434 **Cytokines levels**

435 Serum concentrations of different cytokines were assessed before and after
436 intervention and results are expressed as Mean \pm SD. In the probiotic treated group serum
437 levels of IL10 were 3.23 ± 1.22 pg/ml and 9.25 ± 2.6 pg/ml before and after intervention
438 respectively with the difference being significant ($p < 0.05$). In the placebo group serum
439 IL10 levels were 2.47 ± 1.19 pg/ml and 2.97 ± 1.67 pg/ml before and after intervention
440 respectively, this difference was not significant ($p = ns$). Results indicated that the secretion
441 of IL-10 in IBD-UC patients was increased in *B coagulans* Unique IS2 group. In the
442 treatment group serum IL6 levels were 34.13 ± 6.8 pg/ml and 17.64 ± 5.2 pg/ml before and
443 after intervention respectively with the difference being significant ($p < 0.05$). In the placebo
444 group serum IL6 levels were 35.85 ± 7.6 pg/ml and 28.49 ± 6.4 pg/ml before and after
445 intervention respectively and this difference was not significant ($p = ns$). The observed
446 results indicated that the secretion of IL-6 in IBD-UC patients was decreased in *B coagulans*
447 Unique IS2 group. In the probiotic treated group, serum IL17 levels were 42.82 ± 6.9 pg/ml
448 and 28.57 ± 5.4 pg/ml before and after intervention respectively with the difference being
449 significant ($p < 0.05$). In the placebo group serum IL17 levels were 36.73 ± 13.73 pg/ml and
450 33.96 ± 14.74 pg/ml before and after intervention respectively with the difference not being
451 significant ($p = ns$). The observed results indicated that the secretion of serum IL-17 was
452 decreased in IBD-UC patients in the probiotic group. In the probiotic treated group serum
453 IL23 levels were 938.39 ± 56.57 pg/ml and 842.20 ± 69.43 pg/ml before and after
454 intervention respectively with the difference not being significant. In the placebo group
455 serum IL23 levels were 951.59 ± 61.31 pg/ml and 932.02 ± 43.30 pg/ml before and after
456 intervention respectively with the difference not being significant ($p = ns$).

457 In the treatment group serum IL-1 β levels were 358.58 ± 39.29 pg/ml and $267.28 \pm$
458 33.88 pg/ml before and after intervention respectively with the difference being significant (p
459 < 0.05). In the placebo group serum IL-1 β levels were 363.93 ± 35.57 pg/ml and $382.59 \pm$
460 37.50 pg/ml before and after intervention respectively with the difference not being
461 significant ($p = ns$). The observed results indicated that the secretion of serum IL-1 β in IBD-
462 UC patients was increased in *B coagulans* Unique IS2 group. In the treatment group serum
463 TNF- α levels were 80.33 ± 13.68 pg/ml and 69.16 ± 14.79 pg/ml before and after
464 intervention respectively with the difference not significant whereas in the placebo group
465 serum TNF- α levels were 76.35 ± 14.72 pg/ml and 79.39 ± 13.8 pg/ml before and after
466 intervention respectively with the difference not being significant.

467 **Serum serotonin and dopamine levels:**

468 In the treatment group serum serotonin level were 121.48 ± 15.52 ng/ml and $111.30 \pm$
 469 17.74 ng/ml before and after intervention and the difference was not significant. In the
 470 placebo group serotonin level were 118.12 ± 19.25 ng/ml and 109.88 ± 11.23 ng/ml before
 471 and after intervention and the difference was not significant. In the treatment group serum
 472 dopamine level were 8.51 ± 2.52 pg/ml and 11.74 ± 2.25 pg/ml before and after intervention
 473 and the difference was not significant. In the placebo group dopamine level were 8.48 ± 2.89
 474 pg/ml and 10.89 ± 2.99 pg/ml, before and after intervention and the difference was not
 475 significant. There were changes in serotonin and dopamine levels in the subjects before and
 476 after intervention but the difference was not significant.

477 **Table 1: Serum Cytokines, serotonin and dopamine levels in pre and post intervention**
 478 **samples in treatment and placebo group**

Cytokine (pg/ml)	<i>Bacillus coagulans</i> Unique IS2 group			Placebo group		
	Pre	Post	P value	Pre	Post	P value
IL-10	3.23 ± 1.22	9.25 ± 2.6	<0.05	2.47 ± 1.19	2.97 ± 1.67	NS
IL-6	34.13 ± 6.8	17.64 ± 5.2	<0.05	35.85 ± 7.6	28.49 ± 6.4	NS
IL-17	42.82 ± 6.9	28.57 ± 5.4	<0.05	36.73 ± 13.7	33.96 ± 14.74	NS
IL-23	938.39 ± 56.5	842.20 ± 69.4	NS	951.59 ± 61.3	932.02 ± 43.30	NS
IL-1 β	358.58 ± 39.2	267.28 ± 33.8	<0.05	363.93 ± 35.5	382.59 ± 37.50	NS
TNF- α	80.33 ± 13.6	69.16 ± 14.7	NS	76.35 ± 14.7	79.39 ± 13.8	NS
Serotonin (ng/ml)	121.48 ± 15.5	111.30 ± 17.7	NS	118.12 ± 19.2	109.88 ± 11.23	NS
Dopamine (pg/ml)	8.51 ± 2.52	11.74 ± 2.2	NS	8.48 ± 2.89	10.89 ± 2.99	NS

479

480 **Effect on disease symptoms**

481 Symptoms of disease were assessed based on patient complaint and SCCAI score was
 482 calculated for IBD-UC patients as per standard protocol. The decrease in the SCCAI score
 483 indicates the reduction in the severity of symptoms and increase in the score indicates the
 484 augmentation in the severity of the symptom of UC. In this study reduction of 1 value in
 485 SCCAI score was considered as decrease in SCCAI score. The SCCAI score was decreased
 486 post intervention in 43.75 % of the patients in the probiotic treated group which was
 487 significantly high ($p < 0.05$) as compared to placebo where the decrease in SCCAI score was
 488 reported in 28.57 % patients.

489 **Effect on physical, behavioral and psychological parameters**

490 The enrolled subjects were assessed before and after intervention for the different
491 physical symptoms, behavioral and psychological symptoms including stiff or tense muscles,
492 heartburn, headache, shakiness or tremor, sleep problem, difficulty in completing work,
493 procrastination, overwhelming, feeling of depression, trouble relaxing, nervousness, poor
494 concentration, quick temper and restlessness. All the symptoms were evaluated based on
495 scores, the decrease in the score indicates the reduction in the severity of symptoms and
496 increase in the score indicates the augmentation in the severity of the symptom. In this study
497 the complaint of muscles stiffness was reduced post intervention in 41.66 % and 29.16 %
498 subjects in the treatment and placebo group respectively and the difference between the
499 groups was significant ($p < 0.05$). The complaint of heartburn was reduced post intervention
500 in 43.75 % and 31.25 % subjects in the treatment and placebo group respectively and the
501 difference between the groups was significant ($p < 0.05$). The complaints of headache were
502 reduced post intervention in 37.5 % and 33.33 % subjects in the probiotic and placebo group
503 respectively with no significant difference between groups. The complaint of shakiness or
504 tremor was reduced post intervention in 33.33 % and 31.25 % subjects in the treatment and
505 placebo group with no significant difference between groups.

506 The complaint of sleep problem was reduced post intervention in 41.66 % and 27.08
507 % subjects in the treatment and placebo group respectively with the difference between
508 groups being significant ($p < 0.05$). The complaint of procrastination was reduced in 31.25 %
509 subjects and 35.4 % subjects in the treatment and placebo group respectively with no
510 significant difference between groups. The complaints of difficulty in completing work or
511 assignments was decreased post intervention in 37.5 % subjects and 27.08 % subjects in the
512 probiotic treated and placebo group respectively with the difference between groups being
513 significant ($p < 0.05$). The complaints of overwhelming was reduced post intervention in
514 41.66 % and 31.25 % subjects in the treatment and placebo group respectively and the
515 difference between placebo and treatment groups was significant ($p < 0.05$). The complaints
516 of trouble relaxing was reduced post intervention in 37.5 % and 27.08 % subjects in the
517 treatment group and placebo group respectively with the difference between groups being
518 significant ($p < 0.05$). The complaint of nervousness was reduced post intervention in 33.33
519 % and 29.16 % subjects in the treatment and placebo group respectively with no significant
520 difference between groups. The complaints of depression was reduced post intervention in
521 33.33 % and 31.25 % subjects in the treatment and placebo group respectively with no
522 significant difference between groups. The complaints of poor concentration was reduced

523 post intervention in 47.91 % and 33.3 % subjects in the treatment group and placebo group
 524 respectively with the difference between groups being significant (p<0.05). The complaints
 525 of quick temper was reduced post intervention in 45.83 % and 39.58 % subjects in the
 526 treatment group and placebo group respectively with no significant difference. The
 527 complaints of restlessness was reduced post intervention in 47.91 % and 35.4 % subjects in
 528 the treatment group and placebo group respectively with the difference between groups being
 529 significant (p<0.05). The observed results exhibited improvement in various physical,
 530 behavioral and psychological symptoms of enrolled IBD subjects in the treatment group.

531 **Table 2: Post intervention decrease in symptoms in the enrolled subjects for different**
 532 **physical, behavioural and psychological parameters**
 533

Physical, behavioural and psychological parameters	Post intervention decrease in symptoms (% of total subjects)		
	<i>Bacillus coagulans</i> Unique IS2 group	Placebo group	P value
Muscles stiffness	41.66 %	29.16 %	<0.05
Heartburn	43.75	31.25 %	<0.05
Headache	37.5 %	33.33 %	NS
Shakiness or tremor	33.33 %	31.25 %	NS
Sleep problem	41.66 %	27.08 %	<0.05
Procrastination	31.25 %	35.4 %	NS
Difficulty in completing work or assignments	37.5 %	27.08 %	<0.05
Overwhelming	41.66 %	31.25 %	<0.05
Trouble relaxing	37.5 %	27.08 %	<0.05
Nervousness	33.33 %	29.16 %	NS
Depression	33.33 %	31.25 %	NS
Poor concentration	47.91 %	33.3 %	<0.05
Quick temper	45.83 %	39.58 %	NS
Restlessness	47.91 %	35.4 %	<0.05

534

535 **Safety evaluations:** During and after intervention no adverse events were observed, recorded
 536 and reported in the study which further established the safety of *B coagulans* Unique IS2.

Discussion

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

Targeted microbiota intervention through probiotics and fecal microbiota transplantation are considered as effective therapeutic methods for IBD^{12,33}. Mechanisms of action of probiotics in IBD prevention include increase in beneficial bacteria, inhibition of pathogenic bacteria, immuno-modulation, augmentation of anti-inflammatory responses and enhancement of the intestinal barrier function¹⁴. *Bacillus* species are high heat resistance, acid tolerance and they can survive considerably better than other probiotics in gastric conditions^{34,35}. *B. coagulans* Unique IS-2 is a non-toxic commercial probiotic strain with proven safety and efficacy, long shelf life and stability at room temperature²⁴. Whole genome sequence analysis of *B. coagulans* Unique IS-2 has corroborated its safety with the absence of any toxin genes³⁶. In this study, no severe adverse event was reported, which establish the safety of *B. coagulans* Unique IS-2. Safety and therapeutic efficacy of *B. coagulans* Unique IS-2 has been proven in different disease including Irritable Bowel Syndrome in adult²⁷ and children²⁵, acute-diarrhea²⁶, abdominal pain³⁷, constipation²⁷, oral health³⁸, bacterial vaginosis²⁶, anti-hypercholesterolemic effect²² and liver cirrhosis. This strain also showed anti-inflammatory²⁴ and anti-proliferative effects³⁹.

Post intervention, significant detection of *Bacillus coagulans* in the probiotic treated group demonstrating that this probiotic strain was able to survive in GI tract of IBD patients. Beneficial bacteria provide protection to host against colonization of harmful bacteria and suppress the growth of pathogens by imposing competition for shared niches and nutrients⁴⁰. Results of the present study indicated that *B. coagulans* Unique IS-2 was able to modulate the gut microbiota by increasing beneficial bacteria. Another study also reported that consumption of *B. coagulans* was capable of restoring the microbial imbalance⁴¹ and able to increase populations of *Lactobacillus* and *Bifidobacteria*^{42,43} possibly by consuming free oxygen in the intestine and reduces redox reactions, creating an unfavorable anaerobic and acidic environment to various pathogens⁴³.

Results of the metagenomics analysis revealed that phylum Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were abundant in both the study group which are earlier reported dominated in Indian gut^{44,45}. An increase in the abundance of phylum Firmicutes and Bacteroidetes was observed in post intervention sample in both groups. Decrease in abundance of phylum Proteobacteria and Actinobacteria was observed in post intervention sample in both groups. Other studies also reported decrease in Bacteroides and Firmicutes and increase in Proteobacteria and Actinobacteria in GI

571 disease^{31,46}. It is believed that inflammation is an oxidative state which might promote the
572 outgrowth of aerotolerant taxa such as Proteobacteria and Actinobacteria⁴⁷.

573 The abundance of *Lactobacillus*, *Bifidobacterium* and *Bacillus* genera were increased
574 in post intervention samples in treatment group and decrease in placebo group. *Lactobacillus*
575 and *Bifidobacteria* are among the first colonizers of newborns⁴⁸ and are known for their
576 beneficial effects⁴⁹. The observed high abundance of *Lactobacillus*, *Bifidobacterium* and
577 *Bacillus* genera in treatment group indicated that given probiotic help the gut in restoring
578 these beneficial bacteria. Other studies reported decreased abundance of *Faecalibacterium* in
579 IBD^{50,51}. We observed an increase in abundance of genus *Faecalibacterium* in post
580 intervention samples in treatment group and decrease in placebo group which indicates the
581 given probiotic help the gut in restoring them. Bacterial genera *Lactobacillus*,
582 *Bifidobacterium*, and *Faecalibacterium* have been reported to be protective for mucosal
583 inflammation in the host^{11,52} via several mechanisms, including the up-regulation of the anti-
584 inflammatory cytokine, and down-regulation of inflammatory cytokines⁵³. Studies reported
585 decrease in the genera *Bacteriodes* in IBD^{14,54}. We observed an increase in abundance of
586 genus *Bacteroides* in post intervention samples in treatment group and decrease in placebo
587 group which indicates that the given probiotic intervention may help to restore the genus
588 *Bacteroides* in enrolled IBD patients. A decrease in the abundance of bacterial genera
589 *Dialister*, *Roseburia*, *Megasphaera* was observed in post intervention samples in treatment
590 group and increase in placebo group. A decrease in the abundance of *Blautia* species in the
591 IBD patients was reported⁵⁵. We observed an increase in OTUs of genus *Blautia* in post
592 intervention samples in both treatment and placebo group. An increase in abundance of
593 genus *Alistipes* in post intervention samples in treatment group and decrease in placebo
594 group were observed. Gut microbiota study in the IBD patients reported that some of the
595 *Faecalibacterium*, *Bacteroides* and *Alistipes* species have shown significant contribution to
596 metabolic pathway transcription⁵⁶. The abundance of some of bacterial taxon was low but
597 these may play important role in gut function as reported earlier⁵⁷.

598 The improper host immune response against GI microbiota is considered to be the
599 main reason in causing severe inflammation⁴⁰. Studies have reported the changes in the serum
600 levels of anti-inflammatory cytokine (IL-10) and pro-inflammatory cytokines (IL-6, IL-12,
601 TNF- α , INF- γ) in GI disorders⁵⁸. However, the serum cytokine profiling of IBD patients
602 remains less reported. In the present study significant increase was observed in IL-10 levels
603 in treatment group which indicated that the probiotic strain was able to increase the secretion
604 of IL-10 in IBD patients in the treatment group. Other studies have reported the association of

605 IBD patients with anti-inflammatory cytokines IL-10⁵⁹ and IL-10 secretion increased during
606 disease recovery in IBD patients⁶⁰. It is also reported that inactivation of IL-10 leads to
607 increased release of pro-inflammatory cytokines⁶¹.

608 In the present study we observed the significant decrease in IL6 (p <0.05), IL17 (p
609 <0.05), IL23 (p <0.05), and IL-1 β (p <0.05), TNF- α in treatment group which indicated the
610 probiotic intervention was able to modulate the secretion of pro-inflammatory cytokines.
611 Previous studies have reported increased expression of IL-6 may be an intestinal
612 inflammatory mediator of IBD⁶⁴. Studies have reported that the expression of IL-6 was
613 predominantly detected in IBD and an association between serum levels of IL-6 and disease
614 activity⁶². A study reported IL6 in active UC 26 +/- 10 pg/ml and in inactive UC < 10 pg/ml⁶³
615 and this suggested that increased expression of IL-6 may be an intestinal inflammatory
616 mediator of IBD. IL-17 induces the production of many other pro-inflammatory cytokines,
617 including IL-6, TNF- α , and IL-1 β , which leads to localizing and amplifying inflammation.
618 IL-17 was reported to be increased in intestinal tissue and serum of IBD patients^{64,65}. IL-1 β is
619 a pro-inflammatory cytokines play important role in the inflammation in patients with IBD
620 and an elevation in IL-1 β levels are associated with increased disease severity⁶⁶⁻⁶⁸. Studies
621 reported that the improper level of serotonin and dopamine increases the severity of IBD⁶⁹.
622 Serum serotonin and dopamine were also evaluated in this study but no significant change
623 was observed in both groups.

624 Results of the study indicated that *B coagulans* Unique IS-2 along with SMT was able
625 to reduce the severity of symptom and improve physical and psychological parameters in
626 IBD patient in the treatment group. These results are similar to another study which reported
627 that a probiotic mixture (VSL#3) reduced the expression of inflammatory cytokines and the
628 severity of disease in UC patients⁷⁰. A meta-analysis also reported that probiotics can benefit
629 IBD treatment during combined use of probiotics and standard therapy⁷¹. A study with *B.*
630 *coagulans* Unique IS-2 in children with functional abdominal pain indicated reduction of
631 abdominal pain in the probiotic treated group³⁷. Another study reported *B. coagulans* Unique
632 IS-2 was effective in the treatment of IBS with a significant decrease in the intensity of pain
633 in the probiotic treated group²⁵. Probiotics can reduce inflammation and disease symptoms
634 by modulation of the mucosal immune system, increased intestinal barrier function,
635 competitive prohibition of pathogens, production of antimicrobial factors⁷² amplification of
636 the intestinal tight junctions to stabilize the permeability, normalize bowel movements and
637 reduce visceral hypersensitivity⁷³⁻⁷⁵.

638 **Summary and Conclusion**

639 The results of the study showed that the *B coagulans* Unique IS-2 is able to survive in
640 GI tract of IBD patients. *B. coagulans* Unique IS-2 was able to enhance bacterial genera
641 *Lactobacillus*, *Bifidobacterium*, *Faecalibacterium*, *Bacteroides*, *Megamonas*, *Lachnospira*,
642 *Blautia* and *Alistipes* in post intervention samples in the treatment group. A decrease in
643 bacterial genera *Sutterella*, *Dialister*, *Roseburia* and *Megasphaera* was observed in post
644 intervention samples in the treatment group. Variable alterations were also observed in the
645 abundance of different bacterial taxon including phylum, class, order, family, and genus in
646 the post intervention sample of the treatment group. *B coagulans* Unique IS-2 was able to
647 modulate the secretion of serum cytokines in IBD patients. The level of IL-10 was increased
648 significantly post intervention in treatment group. The secretion of cytokines, IL-6, IL-1 β ,
649 TNF- α , IL -17 and IL -23 were variably decreased post intervention in the treatment group.
650 No significant change in serum serotonin and dopamine was observed in both treatment and
651 placebo groups. A reduction in the severity of symptoms of disease and significant
652 improvement in the physical and psychological parameter were observed post intervention in
653 enrolled subjects in the treatment group. Observed results demonstrated that *B coagulans*
654 Unique IS2 showed beneficial effect in IBD-UC patients when administered along with
655 standard medical treatment (SMT). Study was registered with Clinical Trials Registry India
656 (CTRI) - (CTRI registration No.- CTRI/2019/11/022087).

657

658 **Conflict of interest statement:** RSM and JN are employed by manufacturer of probiotics
659 (Unique Biotech Ltd) and they wish to state that the study was conducted independently with
660 no intervention on their part during the study. All other authors declare no conflict of interest.

661 **Author Contribution:** VDB- Recruited the subjects, carried out experiments, analyzed data
662 and wrote final manuscript, DD - carried out experiments and analyzed the data, PS - carried
663 out experiments and analyzed the data. SK clinical assessment and monitoring of subjects,
664 RSM, JN – drafted study proposal and manuscript, VA- clinical assessment and monitoring
665 of subjects, designed the trial, supervised the study. RC -conceptualizes the study, finalized
666 study proposal, designed the trial and supervised the study. All the authors read and revised
667 the manuscript and approve the final manuscript.

668 **Acknowledgement:** Authors acknowledge the financial support from Unique Biotech Ltd,
669 Hyderabad, India. Help of Mr. Surender Singh (Laboratory Technician) in microbial culture
670 media and reagent preparation is also acknowledged.

671 **References**

- 672 1. Acharyya BC. Incidence of Inflammatory Bowel Disease in a Tertiary Centre of Eastern
673 India. *ARGH*; 9. Epub ahead of print 26 July 2018. DOI:
674 10.19080/ARGH.2018.09.555774.
- 675 2. Kedia S, Ahuja V. Is the emergence of inflammatory bowel disease a prime example of
676 ‘the third epidemiological transition’? *Indian J Gastroenterol* 2018; 37: 183–185.
- 677 3. Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease
678 burden. *Intest Res* 2017; 15: 138–141.
- 679 4. Kedia S, Ahuja V. Epidemiology of Inflammatory Bowel Disease in India: The Great
680 Shift East. *Inflamm Intest Dis* 2017; 2: 102–115.
- 681 5. Kim YS, Jung S-A, Lee K-M, et al. Impact of inflammatory bowel disease on daily life:
682 an online survey by the Korean Association for the Study of Intestinal Diseases. *Intest*
683 *Res* 2017; 15: 338–344.
- 684 6. Sigall-Boneh R, Levine A, Lomer M, et al. Research Gaps in Diet and Nutrition in
685 Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group
686 [Dietitians of ECCO]. *J Crohns Colitis* 2017; 11: 1407–1419.
- 687 7. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current
688 therapy. *Curr Pharm Des* 2014; 20: 1082–1096.
- 689 8. Maunder RG, Levenstein S. The role of stress in the development and clinical course of
690 inflammatory bowel disease: epidemiological evidence. *Curr Mol Med* 2008; 8: 247–
691 252.
- 692 9. Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances
693 in Biologic Therapies. *Immune Netw* 2017; 17: 25–40.
- 694 10. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory
695 bowel disease. *Clin J Gastroenterol* 2018; 11: 1–10.
- 696 11. Zuo T, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of
697 Inflammatory Bowel Disease. *Front Microbiol* 2018; 9: 2247.
- 698 12. Dong L-N, Wang M, Guo J, et al. Role of intestinal microbiota and metabolites in
699 inflammatory bowel disease. *Chin Med J (Engl)* 2019; 132: 1610–1614.
- 700 13. Sun Y, Li L, Xia Y, et al. The gut microbiota heterogeneity and assembly changes
701 associated with the IBD. *Sci Rep* 2019; 9: 440.
- 702 14. Khan I, Ullah N, Zha L, et al. Alteration of Gut Microbiota in Inflammatory Bowel
703 Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome.
704 *Pathogens* 2019; 8: 126.
- 705 15. Manocha M, Khan WI. Serotonin and GI Disorders: An Update on Clinical and
706 Experimental Studies. *Clin Transl Gastroenterol* 2012; 3: e13.
- 707 16. O’Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the
708 brain-gut-microbiome axis. *Behav Brain Res* 2015; 277: 32–48.
- 709 17. Tolstanova G, Deng X, Ahluwalia A, et al. Role of Dopamine and D2 Dopamine
710 Receptor in the Pathogenesis of Inflammatory Bowel Disease. *Dig Dis Sci* 2015; 60:
711 2963–2975.
- 712 18. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-
713 enteric microbiota axis. *Nat Rev Gastroenterol Hepatol* 2009; 6: 306–314.

- 714 19. Reber SO. Stress and animal models of inflammatory bowel disease—An update on the
715 role of the hypothalamo–pituitary–adrenal axis. *Psychoneuroendocrinology* 2012; 37: 1–
716 19.
- 717 20. Sudha M, Chauhan P, Dixit K, et al. Molecular Typing and Probiotic Attributes of a New
718 Strain of *Bacillus coagulans* - Unique IS-2: a Potential Biotherapeutic Agent. *undefined*,
719 [https://www.semanticscholar.org/paper/Molecular-Typing-and-Probiotic-Attributes-of-a-](https://www.semanticscholar.org/paper/Molecular-Typing-and-Probiotic-Attributes-of-a-New-Sudha-Chauhan/f8bbf999bc57cb022d282e9ad13442f877914db7)
720 [New-Sudha-Chauhan/f8bbf999bc57cb022d282e9ad13442f877914db7](https://www.semanticscholar.org/paper/Molecular-Typing-and-Probiotic-Attributes-of-a-New-Sudha-Chauhan/f8bbf999bc57cb022d282e9ad13442f877914db7) (2010, accessed
721 28 July 2021).
- 722 21. Konuray G, Erginkaya Z. Potential Use of *Bacillus coagulans* in the Food Industry.
723 *Foods* 2018; 7: 92.
- 724 22. Ratna Sudha M, Radkar N, Maurya A. Effect of supplementation of probiotic *Bacillus*
725 *coagulans* unique IS-2 (ATCC PAT-11748) on hypercholesterolemic subjects: A clinical
726 study. *International Journal of Probiotics and Prebiotics* 2011; 6: 89–94.
- 727 23. Ratna Sudha M, Bhonagiri S. Efficacy of *Bacillus coagulans* strain unique IS-2 in the
728 treatment of patients with acute diarrhea. *International Journal of Probiotics and*
729 *Prebiotics* 2012; 7: 33–37.
- 730 24. Sudha RM, Sunita M, Sekhar BM. Safety studies of *Bacillus coagulans* unique IS-2 in
731 rats: Morphological, biochemical and clinical evaluations. *International Journal of*
732 *Probiotics & Prebiotics* 2016; 11: 43+.
- 733 25. Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of *Bacillus coagulans* Unique IS2 in
734 treatment of irritable bowel syndrome in children: a double blind, randomised placebo
735 controlled study. *Benef Microbes* 2018; 9: 563–572.
- 736 26. Ratna Sudha M, Yelikar KA, Deshpande S. Clinical Study of *Bacilluscoagulans* Unique
737 IS-2 (ATCC PTA-11748) in the Treatment of Patients with Bacterial Vaginosis. *Indian J*
738 *Microbiol* 2012; 52: 396–399.
- 739 27. Madempudi RS, Neelamraju J, Ahire JJ, et al. *Bacillus coagulans* Unique IS2 in
740 Constipation: A Double-Blind, Placebo-Controlled Study. *Probiotics Antimicrob*
741 *Proteins* 2020; 12: 335–342.
- 742 28. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. *Gut*
743 1998; 43: 29–32.
- 744 29. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL).
745 *Psychological Measurements in Psychopharmacology* 1974; 7: 79–110.
- 746 30. Kleppang AL, Hagquist C. The psychometric properties of the Hopkins Symptom
747 Checklist-10: a Rasch analysis based on adolescent data from Norway. *Fam Pract* 2016;
748 33: 740–745.
- 749 31. Bamola VD, Ghosh A, Kapardar RK, et al. Gut microbial diversity in health and disease:
750 experience of healthy Indian subjects, and colon carcinoma and inflammatory bowel
751 disease patients. *Microb Ecol Health Dis* 2017; 28: 1322447.
- 752 32. Ahmed N, Daniel B, Varghese J, et al. Oropharyngeal microbiome of an HIV-positive
753 patient. *Microbial Pathogenesis* 2020; 139: 103805.
- 754 33. Hudson LE, Anderson SE, Corbett AH, et al. Gleaning Insights from Fecal Microbiota
755 Transplantation and Probiotic Studies for the Rational Design of Combination Microbial
756 Therapies. *Clin Microbiol Rev* 2017; 30: 191–231.

- 757 34. Hyronimus B, Le Marrec C, Sassi AH, et al. Acid and bile tolerance of spore-forming
758 lactic acid bacteria. *Int J Food Microbiol* 2000; 61: 193–197.
- 759 35. Keller D, Verbruggen S, Cash H, et al. Spores of *Bacillus coagulans* GBI-30, 6086 show
760 high germination, survival and enzyme activity in a dynamic, computer-controlled in
761 vitro model of the gastrointestinal tract. *Benef Microbes* 2019; 10: 77–87.
- 762 36. Upadrasta A, Pitta S, Madempudi RS. Draft Genome Sequence of the Spore-Forming
763 Probiotic Strain *Bacillus coagulans* Unique IS-2. *Genome Announc* 2016; 4: e00225-16.
- 764 37. Saneian H, Pourmoghaddas Z, Roohafza H, et al. Synbiotic containing *Bacillus*
765 *coagulans* and fructo-oligosaccharides for functional abdominal pain in children.
766 *Gastroenterol Hepatol Bed Bench* 2015; 8: 56–65.
- 767 38. K MJ, Shenoy N, Talwar A, et al. Clinical effect of pro-biotic containing *Bacillus*
768 *coagulans* on plaque induced gingivitis: A randomised clinical pilot study. *Journal of*
769 *Health and Allied Sciences NU* 2017; 07: 007–012.
- 770 39. Madempudi RS, Kalle AM. Antiproliferative Effects of *Bacillus coagulans* Unique IS2
771 in Colon Cancer Cells. *Nutr Cancer* 2017; 69: 1062–1068.
- 772 40. Kho ZY, Lal SK. The Human Gut Microbiome - A Potential Controller of Wellness and
773 Disease. *Front Microbiol* 2018; 9: 1835.
- 774 41. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of
775 antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA* 2012; 307:
776 1959–1969.
- 777 42. Ara K, Meguro S, Hase T, et al. Effect of Spore-bearing Lactic Acid-forming Bacteria (
778 *Bacillus coagulans* SANK 70258) Administration on the Intestinal Environment,
779 Defecation Frequency, Fecal Characteristics and Dermal Characteristics in Humans and
780 Rats. *Microbial Ecology in Health and Disease* 2002; 14: 4–13.
- 781 43. Cao J, Yu Z, Liu W, et al. Probiotic characteristics of *Bacillus coagulans* and associated
782 implications for human health and diseases. *Journal of Functional Foods* 2020; 64:
783 103643.
- 784 44. Jain A, Li XH, Chen WN. Similarities and differences in gut microbiome composition
785 correlate with dietary patterns of Indian and Chinese adults. *AMB Expr* 2018; 8: 104.
- 786 45. Gupta A, Dhakan DB, Maji A, et al. Association of *Flavonifractor plautii*, a Flavonoid-
787 Degrading Bacterium, with the Gut Microbiome of Colorectal Cancer Patients in India.
788 *mSystems*; 4: e00438-19.
- 789 46. Ryan FJ, Ahern AM, Fitzgerald RS, et al. Colonic microbiota is associated with
790 inflammation and host epigenomic alterations in inflammatory bowel disease. *Nat*
791 *Commun* 2020; 11: 1512.
- 792 47. Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? *Nat*
793 *Rev Gastroenterol Hepatol* 2017; 14: 573–584.
- 794 48. Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal
795 adenoma-carcinoma sequence. *Nat Commun* 2015; 6: 6528.
- 796 49. Flint HJ, Scott KP, Duncan SH, et al. Microbial degradation of complex carbohydrates in
797 the gut. *Gut Microbes* 2012; 3: 289–306.
- 798 50. Becker C, Neurath MF, Wirtz S. The Intestinal Microbiota in Inflammatory Bowel
799 Disease. *ILAR J* 2015; 56: 192–204.

- 800 51. Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the
801 Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel
802 disease. *J Clin Microbiol* 2014; 52: 398–406.
- 803 52. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients
804 with Crohn’s disease and their unaffected relatives. *Gut* 2011; 60: 631–637.
- 805 53. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-
806 inflammatory commensal bacterium identified by gut microbiota analysis of Crohn
807 disease patients. *Proc Natl Acad Sci U S A* 2008; 105: 16731–16736.
- 808 54. Nemoto H, Kataoka K, Ishikawa H, et al. Reduced diversity and imbalance of fecal
809 microbiota in patients with ulcerative colitis. *Dig Dis Sci* 2012; 57: 2955–2964.
- 810 55. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-
811 onset Crohn’s disease. *Cell Host Microbe* 2014; 15: 382–392.
- 812 56. Schirmer M, Franzosa EA, Lloyd-Price J, et al. Dynamics of metatranscription in the
813 inflammatory bowel disease gut microbiome. *Nat Microbiol* 2018; 3: 337–346.
- 814 57. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome.
815 *Nature* 2011; 473: 174–180.
- 816 58. Bennet SMP, Polster A, Törnblom H, et al. Global Cytokine Profiles and Association
817 With Clinical Characteristics in Patients With Irritable Bowel Syndrome. *Am J*
818 *Gastroenterol* 2016; 111: 1165–1176.
- 819 59. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria
820 expressing interleukin-10 in Crohn’s disease. *Clin Gastroenterol Hepatol* 2006; 4: 754–
821 759.
- 822 60. Mitsuyama K, Tomiyasu N, Takaki K, et al. Interleukin-10 in the pathophysiology of
823 inflammatory bowel disease: increased serum concentrations during the recovery phase.
824 *Mediators Inflamm* 2006; 2006: 26875.
- 825 61. Ma X, Yan W, Zheng H, et al. Regulation of IL-10 and IL-12 production and function in
826 macrophages and dendritic cells. *F1000Res* 2015; 4: F1000 Faculty Rev-1465.
- 827 62. Mavropoulou E, Mechie N-C, Knoop R, et al. Association of serum interleukin-6 and
828 soluble interleukin-2-receptor levels with disease activity status in patients with
829 inflammatory bowel disease: A prospective observational study. *PLOS ONE* 2020; 15:
830 e0233811.
- 831 63. Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but
832 not disease specificity in inflammatory bowel disease. *J Clin Gastroenterol* 1995; 20:
833 123–126.
- 834 64. Kuwabara T, Ishikawa F, Kondo M, et al. The Role of IL-17 and Related Cytokines in
835 Inflammatory Autoimmune Diseases. *Mediators of Inflammation* 2017; 2017: e3908061.
- 836 65. Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, et al. Crohn’s Disease and Ulcerative
837 Colitis Show Unique Cytokine Profiles. *Cureus* 2017; 9: e1177.
- 838 66. Mao L, Kitani A, Strober W, et al. The Role of NLRP3 and IL-1 β in the Pathogenesis of
839 Inflammatory Bowel Disease. *Front Immunol* 2018; 9: 2566.
- 840 67. Coccia M, Harrison OJ, Schiering C, et al. IL-1 β mediates chronic intestinal
841 inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells
842 and CD4(+) Th17 cells. *J Exp Med* 2012; 209: 1595–1609.

- 843 68. Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel
844 disease--enhanced production during active disease. *Gut* 1990; 31: 686–689.
- 845 69. Marcus MM, Jardemark K, Malmerfelt A, et al. Augmentation by escitalopram, but not
846 citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral,
847 biochemical, and electrophysiological evidence. *Synapse* 2012; 66: 277–290.
- 848 70. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate
849 ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical
850 treatment: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol*
851 2010; 105: 2218–2227.
- 852 71. Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of
853 inflammatory bowel diseases: A meta analysis and systematic review. *Journal of*
854 *Cellular Physiology* 2018; 233: 2091–2103.
- 855 72. Schlee M, Harder J, Köten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte
856 beta-defensin 2. *Clin Exp Immunol* 2008; 151: 528–535.
- 857 73. Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irritable bowel
858 syndrome: Updated systematic review with meta-analysis. *World J Gastroenterol* 2015;
859 21: 3072–3084.
- 860 74. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal
861 health and disease. *Nat Rev Gastroenterol Hepatol* 2010; 7: 503–514.
- 862 75. Korterink JJ, Ockeloen L, Benninga MA, et al. Probiotics for childhood functional
863 gastrointestinal disorders: a systematic review and meta-analysis. *Acta Paediatr* 2014;
864 103: 365–372.
- 865